Navigation Links
New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms

Bacillus coagulans significantly reduces abdominal pain and bloating

CLEVELAND, March 24 /PRNewswire/ -- A new study published in the March issue of Postgraduate Medicine found that a strain of probiotic bacteria, Bacillus coagulans GBI-30, PTA-6086 was effective in relieving abdominal pain and bloating in subjects with irritable bowel syndrome (IBS). As many as 25 percent of the U.S. population suffer from IBS, a condition characterized by a number of uncomfortable digestive symptoms and associated with a severe reduction in quality of life. Although there are two prescription drugs for IBS, doctors are limited as to the solutions they can recommend. The new study adds to the growing body of evidence that certain probiotics can help with IBS and provides hope for IBS sufferers of a new option.

(Photo: )

(Logo: )

The study found that subjects taking the Bacillus coagulans probiotic strain, trademarked GanedenBC30 and marketed in the over-the-counter product, Digestive Advantage Irritable Bowel Syndrome, experienced statistically significant reductions in abdominal pain and bloating versus baseline at each of the weekly measurements taken throughout the 8-week study. Subjects taking placebo experienced statistically significant reductions in just two of the weekly abdominal pain measurements and saw no statistically significant effect in bloating. "This study helps confirm that Bacillus coagulans is effective in IBS," said Larysa Hun, M.D., author of the 44 subject study. "A combination of Bacillus coagulans, Lactobacillus acidophilus, and Streptococcus thermophilus was previously shown in a clinical trial to significantly improve IBS symptoms, but it was not possible to determine what effect, if any, each strain had by itself."

IBS is associated with impaired quality of life, psychiatric problems, family disruption, impaired workplace performance, unnecessary tests and surgery, high direct and indirect costs, and even death due to IBS medications or interventions. "IBS is the most common functional gastrointestinal disorder (FGID) and represents a tremendous public health problem," noted Nicholas Talley, M.D., Ph.D., of the Mayo Clinic, an expert on IBS and author of a scientific review article about the impact FGIDs have on society.

Two drugs, alosetron and lubiprostone, are FDA-approved only for certain types of IBS: alosetron is for women with severe IBS-related diarrhea only and has serious potential side effects; lubiprostone is only for women with IBS-related constipation. Doctors commonly recommend over-the-counter medications such as laxatives, antidiarrheals, and bulking agents for IBS. But in a recent interview, Talley said, "they don't work well for most people with IBS."

"We know from consumer data that people who try Digestive Advantage Irritable Bowel Syndrome are more likely to become repeat purchasers of the product than people who try 30 other of the most popular brands of digestive products sold in stores," said Marshall Fong, vice president of marketing at Ganeden Biotech, which helped fund the study through a research grant. "This study and our other IBS studies provide scientific data to support what hundreds of thousands of satisfied consumers already tell us with their strong loyalty to our products."

The study adds to the growing amount of evidence suggesting that some probiotics are effective in relieving various IBS symptoms. Some experts would like to see continued research even if they already recommend probiotics to their patients. Maurizio Fava, M.D., a professor and researcher at Harvard and Massachusetts General Hospital, is beginning a placebo-controlled clinical trial to evaluate the efficacy of Ganeden's probiotic in patients with IBS and depression to test the hypothesis that there are common underlying factors beneath the two conditions that may be impacted by taking the Bacillus coagulans strain of probiotics. In describing a pragmatic approach to probiotics and IBS, Fava said, "While more placebo-controlled studies are necessary to determine whether giving probiotics to large populations of people, such as those with IBS, delivers a better benefit-to-cost or benefit-to-risk than doing nothing or resorting to other alternatives, it doesn't mean that individuals shouldn't take them if their doctor recommends them and they provide relief."

About Ganeden Biotech

Founded in 1996, Ganeden Biotech Inc. is a private company based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the U.S. through its Digestive Advantage and Sustenex brands. It also licenses its patented probiotic bacteria, GanedenBC30, for use in commercial food and beverage applications as well as in medical foods and dietary supplements. GanedenBC30 was found to be Generally Recognized As Safe (GRAS) by an independent expert panel assembled to assess its safety in use as a food ingredient. Digestive Advantage and Sustenex are available at over 40,000 retailers nationwide including Walmart, CVS/pharmacy, Walgreens, Rite-Aid, Stop & Shop, Giant, Publix, Kroger, and Target. For more information, visit,, or

SOURCE Ganeden Biotech
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
2. Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
3. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
4. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
5. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
6. PSA Screening Cuts Deaths by 20%, Says Worlds Largest Prostate Cancer Study
7. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
8. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
9. New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits
10. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
11. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
Post Your Comments:
(Date:11/30/2015)... CHICAGO , Nov. 30, 2015   Nuance ... The National Decision Support Company (NDSC) today ... support and collaboration capabilities that utilize the American College ... and healthcare provider organizations to comply with current ... --> --> By combining clinical ...
(Date:11/30/2015)... Nov. 30, 2015 Booth #4303 – The Imaging ... will exhibit a broader array of products in a new ... of North America in ... meeting will feature X-ray components "At the Heart of Imaging." ... of products from Varian,s Claymount brand, and computer-aided diagnostic software ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... last 15 years, announced today that Michigan-based Family Health Center (FHC) has selected ... over 45 years, FHC was awarded the largest Affordable Care Act grant for ...
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... publishing magazines and websites specializing in independent living, assisted living and all other ... and Alzheimer’s awareness and research remains a top priority. , ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case ... from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint Health ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... software provider, has verified that their Vasont Universal Integrator (VUI) extension unites with ... creating, editing, and managing content as a continuous process with the latest release ...
Breaking Medicine News(10 mins):